# Roopa Ind (NSE: ROOPAIND) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ROOPAIND · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹38 Cr, it ranks 3246th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Chemicals.

Its return on equity was 11.6% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹30 Cr (+1.0% year on year) and net profit −₹1 Cr (−440.5%), on a standalone basis. Promoters held 48.03% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹38 Cr |
| ROE | 11.6% (FY25) |
| ROCE | 21.6% (FY25) |
| Debt to equity | 1.9 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹30 Cr | +1.0% | −₹1 Cr | −440.5% | −₹1.80 |
| Q3 FY26 | ₹34 Cr | +9.1% | ₹1 Cr | +1.3% | ₹0.98 |
| Q2 FY26 | ₹29 Cr | +12.2% | ₹0 Cr | −20.7% | ₹0.59 |
| Q1 FY26 | ₹35 Cr | +1.6% | ₹0 Cr | +3.7% | ₹0.36 |
| Q4 FY25 | ₹30 Cr | +35.1% | ₹0 Cr | −8.7% | ₹0.51 |
| Q3 FY25 | ₹31 Cr | +59.7% | ₹1 Cr | +181.5% | ₹0.97 |
| Q2 FY25 | ₹26 Cr | +81.0% | ₹1 Cr | −3.3% | ₹0.74 |
| Q1 FY25 | ₹35 Cr | +130.8% | ₹0 Cr | +42.1% | ₹0.35 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹121 Cr | ₹2 Cr |
| FY24 | ₹70 Cr | ₹2 Cr |
| FY23 | ₹76 Cr | ₹1 Cr |
| FY22 | ₹51 Cr | ₹1 Cr |
| FY21 | ₹27 Cr | ₹1 Cr |
| FY20 | ₹28 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 48.03%
- Foreign institutions: 0.25%
- Non-institutions: 51.71%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Sandu Pharma](https://app.pivotnow.in/stock/SANDUPHQ) | — | ₹41 Cr | — | — |
| [Medicamen Organ](https://app.pivotnow.in/stock/MEDIORG) | ₹25.45 | ₹38 Cr | 3.5 | — |
| [Lasa Supergenerics](https://app.pivotnow.in/stock/LASA) | — | ₹37 Cr | — | — |
| [JFL Life Scienc](https://app.pivotnow.in/stock/JFLLIFE) | ₹10.30 | ₹34 Cr | 0.2 | — |
| [Chandra Bhagat](https://app.pivotnow.in/stock/CBPL) | — | ₹33 Cr | — | — |
| [Sharma East Ind](https://app.pivotnow.in/stock/SHARMEH) | — | ₹33 Cr | — | — |

## Questions and answers

### What is the market cap of Roopa Ind?

Roopa Ind's market capitalisation is ₹38 Cr (₹38 Cr) at the 22 Oct 2026 close, ranking 3246th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Roopa Ind?

Return on equity was 11.6% in FY25 and return on capital employed was 21.6% in FY25 (standalone figures).

### Is Roopa Ind a debt-free company?

No. Roopa Ind's debt-to-equity ratio was 1.9 in FY25, with total debt of ₹7 Cr.

### What were Roopa Ind's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Roopa Ind reported revenue of ₹30 Cr, +1.0% year on year, and net profit of −₹1 Cr, −440.5% year on year.

### What is the shareholding pattern of Roopa Ind?

As of 30 Jun 2026: promoters 48.03%, foreign institutions 0.25%, non-institutions 51.71%.

### Who are Roopa Ind's competitors?

The listed Pharma & Healthcare companies closest to Roopa Ind by market cap are Sandu Pharma, Medicamen Organ, Lasa Supergenerics, JFL Life Scienc, Chandra Bhagat and Sharma East Ind.

### Is Roopa Ind a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Roopa Ind's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ROOPAIND against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.